ERCC1 and ERCC2 Haplotype Modulates Induced BPDE-DNA Adducts in Primary Cultured Lymphocytes

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Lu, Xiaobo ^a   Liu, Yanhua ^a   Yu, Tao ^a   Xiao, Sha ^a   Bao, Xiaoyan ^a   Pan, Liang ^a   Zhu, Guolian ^a   Cai, Yuan ^a   Liu, Qiufang ^a   Jin, Cuihong ^a   Yang, Jinghua ^a   Wu, Shengwen ^a   An, Li ^a   van der Straaten, Tahar ^b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

7,8 DIHYDROXYBENZO[A]PYRENE 9,10 OXIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ADULT; AGED; ARTICLE; CARCINOGEN DNA INTERACTION; CELLULAR DISTRIBUTION; COMET ASSAY; CONTROLLED STUDY; DISORDERS OF DNA SYNTHESIS AND REPAIR; DNA DAMAGE; DNA REPAIR; ENVIRONMENTAL EXPOSURE; ERCC1 GENE; ERCC2 GENE; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAPLOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LYMPHOCYTE CULTURE; MAJOR CLINICAL STUDY; MALE; SMOKING;

7,8-DIHYDRO-7,8-DIHYDROXYBENZO(A)PYRENE 9,10-OXIDE; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALLELES; BENZO(A)PYRENE; CARCINOGENS; CELLS, CULTURED; DNA ADDUCTS; DNA DAMAGE; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HAPLOTYPES; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SMOKING; XERODERMA PIGMENTOSUM GROUP D PROTEIN; YOUNG ADULT;

EID: 84875936322     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060006     Document Type: Article

References (58)

1. Jernstrom B, Graslund A, (1994) Covalent binding of benzo[a]pyrene 7,8-dihydrodiol 9,10-epoxides to DNA: molecular structures, induced mutations and biological consequences. Biophys Chem 49: 185-99.
2. Cosman M, de los Santos C, Fiala R, Hingerty BE, Singh SB, et al. (1992) Solution conformation of the major adduct between the carcinogen(+)-anti-benzo[a]pyrene diol epoxide and DNA. Proc Natl Acad Sci USA 89: 1914-1918.
3. Haugen A, Becher G, Benestad C, Vahakangas K, Trivers GE, et al. (1986) Determination of polycyclic aromatic hydrocarbons in the urine, benzo(a) pyrene diol epoxide-DNA adducts in lymphocyte DNA, and antibodies to the adducts in sera from coke oven workers exposed to measured amounts of polycyclic aromatic hydrocarbons in the work atmosphere. Cancer Res 46(8): 4178-4183.
4. Miller EC, (1978) Some current perspectives on chemical carcinogenesis in humans and experimental animals: presidential address. Cancer Res 38(6): 1479-1496.
5. Vineis P, Manuguerra M, Kavvoura FK, Guarrera S, Allione A, et al. (2009) A field synopsis on low- penetrance variants in DNA repair genes and cancer susceptibility. J Natl Cancer Inst 101(1): 24-36.
6. Krivak TC, Darcy KM, Tian C, Bookman M, Gallion H, et al. (2011) Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group study. Gynecol Oncol 122(1): 121-126.
7. Benhamuo S, Sarasin A, (2005) ERCC2/XPD gene polymorphisms and lung cancer: a HuGe review. Am J Epidemiol 161(1): 1-14.
8. Benhamuo S, Sarasin A, (2002) ERCC2/XPD gene polymorphisms and cancer risk. Mutagenesis 17(6): 463-469.
9. Kiyohara C, Yoshimasu K, (2007) Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: a meta-analysis. Int J Med Sci 4(2): 59-71.
10. Li Y, Gu S, Wu Q, Li Y, Fu X, et al. (2007) No association of ERCC1 C8092A and T19007C polymorphisms to cancer risk: a meta-analysis. Eur J Hum Genet 15(9): 967-973.
11. Cao C, Zhang YM, Wang R, Sun SF, Chen ZB, et al. (2011) Excision repair cross complementation group 1 polymorphisms and lung cancer risk: a meta-analysis. Chin Med J (Engl) 124(14): 2203-2208.
12. Zhou W, Liu G, Park S, Wang Z, Wain JC, et al. (2005) Gene-smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer. Cancer Epidemiol Biomarkers Prev 14(2)491-496.
13. Yang M, Kim WH, Choi Y, Lee SH, Kim KR, et al. (2006) Effects of ERCC1 expression in peripheral blood on the risk of head and neck cancer. Cancer Epidemiol Biomarkers Prev 15(3): 269-273.
14. Sturgis EM, Dahistrom KR, Spitz MR, Wei Q, (2002) DNA repair gene ERCC1 and ERCC2/XPD polymorphisms and risk of squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 128(9): 1084-1088.
15. Yin J, Vogel U, Gerdes LU, Dybdahl M, Bolund L, et al. (2003) Twelve single nucleotide polymorphisms on chromosome 19q13.2-13.3: linkage disequilibria and associations with basal cell carcinoma in Danish psoriatic patients. Biochem Genet 41: 27-37.
16. Yin J, Rockenbauer E, Hedayati M, Jacobsen NR, Vogel U, et al. (2002) Multiple single nucleotide polymorphisms on human chromosome 19q13.2-3 associate with risk of Basal cell carcinoma. Cancer Epidemiol Biomarkers Prev 11(11): 1449-1453.
17. Rockenbauer E, Bendixen MH, Bukowy Z, Yin J, Jacobsen NR, et al. (2002) Association of chromosome 19q13.2-3 haplotypes with basal cell carcinoma: tentative delineation of an involved region using data for single nucleotide polymorphisms in two cohorts. Carcinogenesis 23(7): 1149-53.
18. Nexo BA, Vogel U, Olsen A, Ketelsen T, Bukowy Z, et al. (2003) A specific haplotype of single nucleotide polymorphisms on chromosome 19q13.2-3 encompassing the gene RAI is indicative of post- menopausal breast cancer before age 55. Carcinogenesis 24(5): 899-904.
19. Shen J, Desai M, Agrawal M, Kennedy DO, Senie RT, et al. (2006) Polymorphisms in nucleotide excision repair genes and DNA repair capacity phenotype in sisters discordant for breast cancer. Cancer Epidemiol Biomarkers Prev 15(9): 1614-9.
20. Skjelbred CF, Saebo M, Nexo BA, Wallin H, Hansteen IL, et al. (2006) Effects of polymorphisms in ERCC1, ASE-1 and RAI on the risk of colorectal carcinomas and adenomas: a case control study. BMC Cancer 6: 175.
21. Hou SM, Falt S, Angelini S, Yang K, Nyberg F, et al. (2002) The XPD variant alleles are associated with increased aromatic DNA adduct level and lung cancer risk. Carcinogenesis 23(4): 599-603.
22. Lunn RM, Helzlsouer KJ, Parshad R, Umbach DM, Harris EL, et al. (2000) XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 21(4): 551-5.
23. Hu Z, Wei Q, Wang X, Shen H, (2004) DNA repair gene XPD polymorphism and lung cancer risk: a meta-analysis. Lung Cancer 46(1): 1-10.
24. Vogel U, Laros I, Jacobsen NR, Thomsen BL, Bak H, et al. (2004) Two regions in chromosome 19q13.2-3 are associated with risk of lung cancer. Mutat Res 546(1-2): 65-74.
25. Shao J, Gu M, Xu Z, Hu Q, Qian L, (2007) Polymorphisms of the DNA gene XPD and risk of bladder cancer in a Southeastern Chinese population. Cancer Genetics Cytogenet 177: 30-36.
26. Yu HP, Wang XL, Sun X, Su YH, Wang YJ, et al. (2004) Polymorphisms in the DNA repair gene XPD and susceptibility to esophageal squamous cell carcinoma. Cancer Genet Cytogenet 154(1): 10-5.
27. Sturgis EM, Zheng R, Li L, Castillo EJ, Eicher SA, et al. (2000) XPD/ERCC2 polymorphisms and risk of head and neck cancer: a case-control analysis. Carcinogenesis 21(12): 2219-23.
28. Zhao H, Wang LE, Li D, Chamberlain RM, Sturgis EM, et al. (2008) Genotypes and haplotypes of ERCC1 and ERCC2/XPD genes predict levels of benzo[a]pyrene diol epoxide-induced DNA adducts in cultured primary lymphocytes from healthy individuals: a genotype-phenotype correlation analysis. Carcinogenesis 29(8): 1560-1566.
29. Li C, Wang LE, Wei Q, (2009) DNA repair phenotype and cancer susceptibility-a mini review. Int J Cancer 124(5): 999-1007.
30. Li D, Wang LE, Chang P, EI-Naggar AK, Sturgis EM, et al. (2007) In vitro Benzo(a)pyrene Diol Epoxide-Induced DNA Adducts and Risk of Squamous Cell Carcinoma of Head and Neck. Cancer Research 67(12): 5628-5634.
31. Li D, Firozi PF, Wang LE, Bosken CH, Spitz MR, et al. (2001) Sensitivity to DNA damage induced by benzo(a)pyrene diol epoxide and risk of lung cancer: a case-control analysis. Cancer Res 61(4): 1445-50.
32. Wei Q, Gu J, Cheng L, Bondy ML, Jiang H, et al. (1996) Benzo(a)pyrene diol epoxide-induced chromosomal aberrations and risk of lung cancer. Cancer Res 56(17): 3975-3979.
33. Pelling JC, Slaga TJ, DiGiovanni J, (1984) Formation and persistence of DNA, RNA, and protein adducts in mouse skin exposed to pure optical enantiomers of 7 beta, 8 alpha-dihydroxy-9alpaha, 10 alpha-epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene in vivo. Cancer Res 44(3): 1081-1086.
34. Melikian AA, Bagheri K, Hecht SS, (1987) Contrasting disposition and metabolism of topically applied benzo(a)pyrene,trans-7,8-dihydroxy-7,8-dihydrobenzo (a)pyrene, and 7 beta, 8alpha-dihydroxy-9alpha, 10alpha-epoxy-7,8,9,10- tetrahydrobenzo(a) pyrene in mouse epidermis in Vivo. Cancer Res 47: 5354-5360.
35. Matter B, Wang G, Jones R, Tretyakova N, (2004) Formation of diastereomeric benzo[a]pyrene diol epoxide-guanine adducts in p53 gene-derived DNA sequences. Chem Res Toxicol 17(6): 731-41.
36. Guza R, Kotandeniya D, Murphy K, Dissanayake T, Lin C, et al. (2011) Influence of C-5 substituted cytosine and related nucleoside analogs on the formation of benzo[a]pyrene diol epoxide-dG adducts at CG base pairs of DNA. Nucleic Acids Res 39(9): 3988-4006.
37. Shih MK, Hu ML, (1996) UVA-potentiated damage to calf thymus DNA by Fenton reaction system and protection by para-aminobenzoic acid. Photochem Photobiol 63(3): 286-291.
38. Pavanello S, Gabbani G, Mastrangelo G, Brugnone F, Maccacaro G, et al. (1999) Influence of GSTM1 genotypes on anti-BPDE-DNA adduct levels in mononuclear white blood cells of humans exposed to PAH. Int Arch Occup Environ Health 72(4): 238-46.
39. Kang S, Ju W, Kim JW, Park NH, Song YS, et al. (2006) Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer. Exp Mol Med 38(3): 320-324.
40. Ryu JS, Hong YC, Han HS, Lee LE, Kim S, et al. (2004) Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 44(3): 311-316.
41. Chang PM, Tzeng CH, Chen PM, Lin JK, Lin TC, et al. (2009) ERCC1 codon 118 C>T polymorphism associated with ERCC1 expression and outcome of FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma. Cancer sci 100(2): 278-283.
42. Cheng J, Ha M, Wang Y, Sun J, Chen J, et al. (2012) A C118T polymorphism of ERCC1 and response to cisplatin chemotherapy in patients with late-stage non-small cell lung cancer. J Cancer Res Clin Oncol 138(2): 231-238.
43. Chen P, Wiencke J, Aldape K, Kesler-Diaz A, Miike R, et al. (2000) Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol Biomarkers Prev 9(8): 843-847.
44. Whitehead CM, Winkfein RJ, Fritzler MJ, Rattner JB, (1997) ASE-1:a novel protein of the fibrillar centres of the nucleolus and nucleolus organizer region of mitotic chromosomes. Chromosoma (Berl.) 106: 493-502.
45. Yamazaki T, Hamano Y, Tashiro H, Itoh K, Nakano H, et al. (1999) CAST, a novel CD3ε-binding protein transducing activation signal for interleukin-2 production in T cells. J. Biol. Chem 274: 18173-18180.
46. Hansen RD, Sorensen M, Tjonneland A, Overvad K, Wallin H, et al. (2008) A haplotype of polymorphisms in ASE-1, RAI and ERCC1 and the effects of tobacco smoking and alcohol consumption on risk of colorectal cancer: a danish prospective case-cohort study. BMC Cancer 8: 54.
47. Manuguerra M, Saletta F, Karagas MR, Berwick M, Veglia F, et al. (2006) XRCC3 and XPD/ERCC2 single nucleotide polymorphisms and the risk of cancer: a HuGE review. Am. J. Epidemiol 164: 297-302.
48. Wu W, Zhang W, Qiao R, Chen D, Wang H, et al. (2009) Association of XPD polymorphisms with severe toxicity in non-small cell lung cancer patients in a Chinese population. Clin Cancer Res 15(11): 3889-3895.
49. Malats N (2008) Genetic epidemiology of bladder cancer: scaling up in the identification of low-penetrance genetic markers of bladder cancer risk and progression. Scand J Urol Nephrol Suppl 218: 131-140.
50. Yin J, Liang D, Vogel U, Chang Y, Liu Z, et al. (2009) The polymorphism of DNA repair gene ERCC2/XPD Arg156Arg and susceptibility to breast cancer in a Chinese population. Biochem Genet 47(7-8): 582-590.
51. Lovatt T, Alldersea J, Lear JT, Hoban PR, Ramachandran S, et al. (2005) Polymorphism in the nuclear excision repair gene ERCC2/XPD: association between an exon 6-exon 10 haplotype and susceptibility to cutaneous basal cell carcinoma. Hum. Mutat. 25: 353-359.
52. Chang JS, Wrensch MR, Hansen HM, Sison JD, Aldrich MC, et al. (2008) Nucleotide excision repair genes and risk of lung cancer among San Francisco Bay Area Latinos and African Americans. Int J Cancer 123(9): 2095-2104.
53. Matullo G, Palli D, Peluso M, Guarrera S, Carturan S, et al. (2001) XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects. Carcinogenesis 22(9): 1437-45.
54. Zhai XD, Mo YN, Xue XQ, Zhao GS, Gao LB, et al. (2009) XRCC1 codon 280 and ERCC2 codon 751 polymorphisms and risk of esophageal squamous cell carcinoma in a Chinese population. Bull Cancer 96(10): E61-5.
55. Zhang J, Qiu LX, Leaw SJ, Hu XC, Chang JH, (2010) The association between XPD Asp312Asn polymorphism and lung cancer risk: a meta-analysis including 16,949 subjects. Med Oncol 28(3): 655-660.
56. Spitz MR, Wu X, Wang Y, Wang LE, Shete S, et al. (2001) Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 61(4): 1354-7.
57. Mitra AK, Singh N, Garg VK, Chaturvedi R, Sharma M, et al. (2009) Statistically significant association of the single nucleotide polymorphism (SNP) rs13181 (ERCC2) with predisposition to squamous cell carcinoma of the head and neck (SCCHN) and breast cancer in the north Indian population. J Exp Clin Cancer Res 28(1): 104-112.
58. Topinka J, Hertz-Picciotto I, Dostal M, Chvatalova I, Yap PS, et al. (2007) The DNA repair gene XPD/ERCC2 polymorphisms Arg156Arg (exon 6) and Lys751Gln (exon 23) are closely associated. Toxicol Lett 172(1-2): 85-89.